Investor Relations

Latest Financial Results

FY 2023

Fiscal Year Ended Dec 31, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

We are a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have a product program in earlier development that features a unique mechanism of action with potential in chronic diseases.

Stock Information

IR Contacts


CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560
T: (510) 293-8800
F: (510) 293-9090

Investor Relations

LifeSci Advisors, LLC
PJ Kelleher
T: (617) 430-7579

You are leaving our website!